Abstract: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed.

Abstract: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed.

Abstract: Novel cyclic polyamine compounds of the form where A1, each A2 (if present), and A3 are independently selected from C1-C8 alkyl, where each Y is independently selected from H or C1-C4 alkyl, where M is selected from C1-C4 alkyl, where k is 0, 2, or 3, and where R is selected from C1-C32 alkyl, as well as all stereoisomers and salts thereof, are disclosed. Additional compounds where k is 1 and A2 is independently selected from C1-C3 alkyl or C5-C8 alkyl are also disclosed. Cyclic polyamines, where the amide group is reduced to a secondary amino group, and various derivatives of these compounds, are also described. Synthetic methods for the compounds are described. The compounds are useful for treating diseases caused by uncontrolled proliferation of cells, such as cancer, especially prostate cancer, and for inducing intracellular ATP hydrolysis for treatment of other disorders.

Abstract: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed.

Abstract: Novel cyclic polyamine compounds of the form 1